AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|AAPL345.36-1.74 (-0.50%) ▼|ABBV287.64+1.25 (+0.44%) ▲|ABT103.21+0.11 (+0.11%) ▲|ACN245.06+9.90 (+4.21%) ▲|ADBE247.73-0.64 (-0.26%) ▼|AMAT413.18+17.25 (+4.36%) ▲|AMD566.94+6.68 (+1.19%) ▲|AMGN449.95+2.00 (+0.45%) ▲|AMT177.77-6.07 (-3.30%) ▼|AMZN252.54-0.56 (-0.22%) ▼|AVGO347.23+4.90 (+1.43%) ▲|AXP316.12+3.21 (+1.02%) ▲|BA166.71-1.47 (-0.87%) ▼|BAC51.08+0.40 (+0.79%) ▲|BKNG148.00-2.15 (-1.43%) ▼|BLK1,150.65+14.60 (+1.29%) ▲|BMY60.42-1.13 (-1.84%) ▼|BNY148.96+1.38 (+0.94%) ▲|BRK-B544.11+1.12 (+0.21%) ▲|C124.09+1.40 (+1.14%) ▲|CAT715.96+2.65 (+0.37%) ▲|CL91.91-0.26 (-0.28%) ▼|CMCSA21.68-0.17 (-0.76%) ▼|COF204.41+0.97 (+0.47%) ▲|COP150.26+2.30 (+1.55%) ▲|COST983.47-8.67 (-0.87%) ▼|CRM240.71-0.18 (-0.07%) ▼|CSCO109.93-1.45 (-1.30%) ▼|CVS90.66-0.47 (-0.52%) ▼|CVX231.27+3.04 (+1.33%) ▲|DE640.21+0.63 (+0.10%) ▲|DHR234.37+2.37 (+1.02%) ▲|DIS109.14-1.09 (-0.99%) ▼|DUK124.73-0.07 (-0.06%) ▼|EMR167.49+1.22 (+0.73%) ▲|FDX301.65-5.45 (-1.77%) ▼|GD354.34-0.55 (-0.16%) ▼|GE303.32+5.66 (+1.90%) ▲|GEV890.28-4.80 (-0.54%) ▼|GILD159.23+0.15 (+0.09%) ▲|GM81.11+0.57 (+0.71%) ▲|GOOG320.44+3.61 (+1.14%) ▲|GOOGL323.80+3.22 (+1.00%) ▲|GS923.33+11.56 (+1.27%) ▲|HD318.52+0.02 (+0.01%) ▲|HON219.28+0.47 (+0.21%) ▲|IBM251.45+1.20 (+0.48%) ▲|INTC93.80+0.06 (+0.06%) ▲|INTU330.13+1.68 (+0.51%) ▲|ISRG447.28+1.40 (+0.31%) ▲|JNJ270.25+1.52 (+0.57%) ▲|JPM339.65+3.86 (+1.15%) ▲|KO91.83+0.65 (+0.71%) ▲|LIN508.40-0.25 (-0.05%) ▼|LLY1,286.30+4.39 (+0.34%) ▲|LMT629.32+6.33 (+1.02%) ▲|LOW198.75+0.57 (+0.29%) ▲|LRCX254.12+13.27 (+5.51%) ▲|MA613.49+3.64 (+0.60%) ▲|MCD251.60+2.13 (+0.85%) ▲|MDLZ61.87-0.48 (-0.77%) ▼|MDT94.87+0.92 (+0.98%) ▲|META613.34-6.85 (-1.10%) ▼|MMM172.23+0.65 (+0.38%) ▲|MO73.48-0.01 (-0.01%) ▼|MRK140.34-1.49 (-1.05%) ▼|MS189.48+2.57 (+1.38%) ▲|MSFT528.46-2.88 (-0.54%) ▼|MU972.96+44.20 (+4.76%) ▲|NEE81.95-0.47 (-0.57%) ▼|NFLX61.76-0.76 (-1.22%) ▼|NKE37.26-0.30 (-0.80%) ▼|NOW150.63-4.15 (-2.68%) ▼|NVDA217.08-0.87 (-0.40%) ▼|ORCL130.98+0.45 (+0.34%) ▲|PEP132.30-1.20 (-0.90%) ▼|PFE29.38-0.43 (-1.43%) ▼|PG159.22-0.01 (-0.01%) ▼|PLTR194.37-4.36 (-2.19%) ▼|PM202.89+0.27 (+0.13%) ▲|QCOM181.52-2.66 (-1.44%) ▼|RTX197.12+2.52 (+1.30%) ▲|SBUX104.33+1.29 (+1.25%) ▲|SCHW88.86-0.44 (-0.49%) ▼|SO92.58-0.07 (-0.08%) ▼|SPG212.19-0.10 (-0.04%) ▼|T21.04+0.10 (+0.45%) ▲|TMO700.50+7.48 (+1.08%) ▲|TMUS146.74-0.09 (-0.06%) ▼|TSLA401.00-6.46 (-1.59%) ▼|TXN305.50-3.41 (-1.10%) ▼|UBER65.57-0.21 (-0.32%) ▼|UNH412.43+2.04 (+0.50%) ▲|UNP301.70+1.82 (+0.61%) ▲|UPS104.89-1.20 (-1.13%) ▼|USB59.65-0.10 (-0.16%) ▼|V401.72-0.15 (-0.04%) ▼|VZ43.76-0.18 (-0.40%) ▼|WFC84.38+1.72 (+2.07%) ▲|WMT118.74-0.58 (-0.49%) ▼|XOM183.42+3.51 (+1.95%) ▲|
13.7 C
New York
Wednesday, October 28, 2026

Tag: oral

newsFORsourcecompanycontentinformation1releasesmarket

ESMO 2026 | Professors Jie Wang, Zhijie Wang and Jianchun Duan’s Team Reports 95.2% Disease Control With LK101 Combination Maintenance Therapy in Advanced NSCLC

BEIJING, Oct. 25, 2026 /PRNewswire/ -- On October 24, 2026, in Madrid, Spain, the team of Professors Jie Wang, Zhijie Wang and Jianchun Duan at...

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for...

Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity

- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical models.- ASC39 demonstrated eloralintide-like selectivity for...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 26, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026

SHANGHAI and HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to...

Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented...

HONG KONG, Oct. 25, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational Phase...

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer

Responses were deep and durable, with 65% ongoing at clinical cutoffResults support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor,...

New data on Lilly’s investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer

Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy in first-line advanced KRAS G12C-mutant...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 24, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsOral

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers